We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 25

EU Court of Justice nixes patents for stem-cell inventions involving human embryo destruction

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 20 2011

The European Union (EU) Court of Justice has determined that EU patent law does not protect neural precursor cells and the processes for their production from embryonic stem cells

EU Court of Justice interprets law extending patent protection for medicinal products

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • December 15 2011

The Court of Justice of the European Union (ECJ) has issued two rulings interpreting EU law at the request of British courts addressing whether drug makers can obtain a supplementary protection certificate (SPC), which extends patent protection, for products with active ingredients additional to those specified in the original patent

Public-private EU partnership to fund stem cell banking and distribution

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • February 13 2014

A consortium of public and private partners has reportedly formed to establish a European induced pluripotent stem (iPS) cell bank with the goal of

EU adds pharmaceuticals to water pollution watch list

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety

Researchers protest ECJ advocate general’s position on patenting stem cell technologies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 5 2011

Viewing the issue as a matter of morality, the advocate general of the European Court of Justice (ECJ) recently delivered a non-binding ruling that would render unpatentable the cells removed from the human embryo at the blastocyst stage, because the removal involves the embryo's destruction

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."

EU medical device manufacturers address plan to change regulatory directives

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of

European markets less than enthusiastic over biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • December 12 2013

While Europe has had a regulatory approval pathway for biosimilar drug products for some years, their use reportedly remains anemic. Physicians are

EU trade group issues voluntary code for disclosures by pharma companies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a "Code on Disclosure of Transfers of Value from

Wellcome Trust creates £200-million fund for UK, EU biotech startups

  • Shook Hardy & Bacon LLP
  • -
  • European Union, United Kingdom
  • -
  • March 29 2012

The U.K.-based Wellcome Trust has announced the creation of a £200-million fund to make long-term investments in British and European biotechnology startups